UA76934C2 - Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody - Google Patents

Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody Download PDF

Info

Publication number
UA76934C2
UA76934C2 UA99042469A UA99042469A UA76934C2 UA 76934 C2 UA76934 C2 UA 76934C2 UA 99042469 A UA99042469 A UA 99042469A UA 99042469 A UA99042469 A UA 99042469A UA 76934 C2 UA76934 C2 UA 76934C2
Authority
UA
Ukraine
Prior art keywords
antibody
chain
human
region
sequence
Prior art date
Application number
UA99042469A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of UA76934C2 publication Critical patent/UA76934C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UA99042469A 1996-10-04 1997-03-10 Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody UA76934C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26475696 1996-10-04
PCT/JP1997/003553 WO1998014580A1 (en) 1996-10-04 1997-10-03 Reconstituted human anti-hm1.24 antibody

Publications (1)

Publication Number Publication Date
UA76934C2 true UA76934C2 (en) 2006-10-16

Family

ID=17407753

Family Applications (1)

Application Number Title Priority Date Filing Date
UA99042469A UA76934C2 (en) 1996-10-04 1997-03-10 Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody

Country Status (19)

Country Link
US (2) US6699974B2 (cs)
EP (1) EP0960936B1 (cs)
KR (1) KR100388256B1 (cs)
CN (2) CN1271205C (cs)
AT (1) ATE512224T1 (cs)
AU (1) AU715156B2 (cs)
BR (1) BR9712488A (cs)
CA (1) CA2267072C (cs)
CZ (1) CZ296790B6 (cs)
IL (1) IL129286A0 (cs)
NO (1) NO325178B1 (cs)
PL (1) PL187642B1 (cs)
RU (1) RU2184147C2 (cs)
SK (1) SK44399A3 (cs)
TR (1) TR199900722T2 (cs)
TW (1) TW530064B (cs)
UA (1) UA76934C2 (cs)
WO (1) WO1998014580A1 (cs)
ZA (1) ZA978865B (cs)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297219T1 (de) 1997-02-12 2005-06-15 Chugai Pharmaceutical Co Ltd Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
AU718463B2 (en) * 1997-02-28 2000-04-13 Chugai Seiyaku Kabushiki Kaisha Inhibitor of lymphocyte activation
CA2308007C (en) 1997-10-14 2011-05-17 Chugai Seiyaku Kabushiki Kaisha Enhancer for antibody to lymphocytic tumors
EP1757941B1 (en) * 1998-02-25 2010-03-31 Chugai Seiyaku Kabushiki Kaisha Method for immunochemically assaying anti-hm1.24 antibody
US6602663B1 (en) 1998-09-18 2003-08-05 Chugai Seiyaku Kabushiki Kaisha Method for detection or measuring plasmocytoma cells
DE60021373T2 (de) * 1999-05-10 2006-04-27 Chugai Seiyaku K.K. Verfahren der zellkultivierung
AU784460B2 (en) 1999-08-23 2006-04-06 Chugai Seiyaku Kabushiki Kaisha HM1.24 antigen expression potentiators
WO2001077362A1 (fr) * 2000-04-06 2001-10-18 Chugai Seiyaku Kabushiki Kaisha Dosage immunologique d'anticorps anti hm1 . 24
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
US7592005B2 (en) * 2000-12-28 2009-09-22 Kirin Beer Kabushiki Kaisha Monoclonal antibody
WO2002064159A1 (fr) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs affectant les organes hematopoietiques
WO2002072615A1 (en) 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
EP1378752A4 (en) * 2001-04-13 2004-08-04 Chugai Pharmaceutical Co Ltd METHOD FOR QUANTIFYING ANTIGEN EXPRESSION
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
KR100953520B1 (ko) * 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd METHOD FOR STABILIZING PROTEIN PREPARATION
EP3225625A1 (en) 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
WO2005014651A1 (ja) 2003-08-11 2005-02-17 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗hm1.24抗体
US8603481B2 (en) * 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors
US9296820B2 (en) * 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
AU2005214382B2 (en) * 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
DK1794586T3 (da) * 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
AU2012216702B2 (en) * 2005-08-26 2014-12-04 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
AU2006290433B2 (en) * 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR101790802B1 (ko) * 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
HRP20250713T8 (hr) 2011-09-01 2025-10-24 Chugai Seiyaku Kabushiki Kaisha Postupak priprave pripravka koji sadrži visoko koncentrirana protutijela ultrafiltriranjem
MX2016008498A (es) 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
EP3185004A4 (en) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP3624841A4 (en) 2017-06-15 2021-01-27 Cancer Advances, Inc., COMPOSITIONS AND METHODS OF INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
CN115636142A (zh) 2018-05-28 2023-01-24 中外制药株式会社 填充喷嘴
CA3156803A1 (en) * 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
EP4413998A4 (en) 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd METHOD FOR PREPARING A PRE-FILLED SYRINGE FORMULATION
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
ATE297219T1 (de) * 1997-02-12 2005-06-15 Chugai Pharmaceutical Co Ltd Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
US20020034507A1 (en) * 1997-02-28 2002-03-21 Yasuo Koishihara Inhibitor of lymphocyte activation
RU2221809C2 (ru) * 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
CA2308007C (en) * 1997-10-14 2011-05-17 Chugai Seiyaku Kabushiki Kaisha Enhancer for antibody to lymphocytic tumors
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs

Also Published As

Publication number Publication date
RU2184147C2 (ru) 2002-06-27
CA2267072A1 (en) 1998-04-09
WO1998014580A1 (en) 1998-04-09
CN1765928A (zh) 2006-05-03
KR20000048884A (ko) 2000-07-25
HK1024261A1 (en) 2000-10-05
CZ117399A3 (cs) 1999-09-15
CN1271205C (zh) 2006-08-23
EP0960936A4 (en) 2005-01-19
EP0960936A1 (en) 1999-12-01
IL129286A0 (en) 2000-02-17
CA2267072C (en) 2004-11-30
KR100388256B1 (ko) 2003-06-19
PL187642B1 (pl) 2004-08-31
BR9712488A (pt) 1999-10-19
ZA978865B (en) 1998-04-20
CZ296790B6 (cs) 2006-06-14
EP0960936B1 (en) 2011-06-08
SK44399A3 (en) 2000-05-16
AU715156B2 (en) 2000-01-20
AU4399297A (en) 1998-04-24
US20030129185A1 (en) 2003-07-10
ATE512224T1 (de) 2011-06-15
NO325178B1 (no) 2008-02-11
US6699974B2 (en) 2004-03-02
TW530064B (en) 2003-05-01
PL332742A1 (en) 1999-10-11
US20030045691A1 (en) 2003-03-06
NO991591D0 (no) 1999-03-31
NO991591L (no) 1999-06-01
TR199900722T2 (xx) 1999-12-21
US7892543B2 (en) 2011-02-22
CN1235639A (zh) 1999-11-17

Similar Documents

Publication Publication Date Title
UA76934C2 (en) Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP7595696B2 (ja) Ｃｄ３抗原結合性断片及びその使用
US12534532B2 (en) CLL1-targeting antibody and application thereof
KR100259828B1 (ko) 인체 인터루킨 5 수용체 알파-사슬에 대한 항체
JP4764627B2 (ja) 新生物疾患又は免疫不全を処置するためのヒト化免疫調節性モノクローナル抗体
KR100191152B1 (ko) Cd4 특이적 재조합 항체
AU618989B2 (en) Improvements in or relating to antibodies
CN106939050B (zh) 抗pd1和cd19双特异性抗体及其应用
CN112390891B (zh) 嵌合抗原受体及其构建方法和应用
KR20220050971A (ko) 신규 항-cd39 항체
US20020102653A1 (en) DNA coding for human cell surface antigen
TW201708257A (zh) Ｆｌｔ３及ｃｄ３抗體構築體
JPH05505112A (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
CN110396129A (zh) 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
CN117441020A (zh) 一种增强型嵌合抗原受体（car）细胞的制备及其应用
CN117136071A (zh) 多肽及其在治疗疾病中的用途
US20250064853A1 (en) Anti-cd84 antibodies and chimeric antigen receptors
CN114805581B (zh) 靶向il13ra2的抗体、嵌合抗原受体及其用途
CN118852434B (zh) 一种靶向人cd19抗原的人源化单链抗体及其嵌合抗原受体、免疫细胞与应用
KR20230072536A (ko) 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
US20220267442A1 (en) METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
AU2024274176A1 (en) Antibody specifically binding to cll1, preparation method therefor, and use thereof
CN116113433B (zh) 结合人cd38的抗体、其制备方法和用途
KR102393776B1 (ko) Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
TW202241955A (zh) Ｇａｒｐ蛋白抗體及其應用